Skip to main content
Search

# Organ-on-a-chip

1 related articles

Subscribe to updates
  1. IEEE Spectrum

    Organ chips and computational models have won FDA and NIH policy openings, but validation costs and research culture still slow adoption

    This article traces how animal-testing alternatives known as NAMs—organ chips, organoids and computational simulations—moved from a lung-on-a-chip paper that Science asked to be backed up with mouse experiments, to the 2022 FDA Modernization Act 2.0 authorizing NAMs in preclinical studies, a 2025 FDA pledge to make animal studies the exception, and a September 2026 rule that would replace "animal tests" with "nonclinical tests" in drug regulations, while identifying validation standardization, the high cost of head-to-head comparisons and research-culture inertia as the main bottlenecks.

You’re all caught up